Study Compares Hospitalized Infection Risk for Biologics in RA

This article originally appeared here.
Share this content:
Study Compares Hospitalized Infection Risk for Biologics in RA
Study Compares Hospitalized Infection Risk for Biologics in RA

WEDNESDAY, Sept. 2, 2015 (HealthDay News) -- For patients with rheumatoid arthritis (RA) with prior biologic exposure, the risk of hospitalized infection is increased with etanercept, infliximab, and rituximab versus abatacept, according to a study published online Aug. 28 in Arthritis & Rheumatology.

Huifeng Yun, Ph.D., from the University of Alabama at Birmingham, and colleagues compared risks of hospitalized infections associated with biologics used to treat RA using Medicare data from 2006 to 2011. Patients were followed from initiation of new biologic treatment after previous treatment with a different biologic.

The researchers found that of 31,801 new biologic treatment episodes where patients previously used another biologic, 12.0, 15.2, 5.9, 4.4, 12.4, 28.9, 14.8, and 6.3 percent were with etanercept, adalimumab, certolizumab, golimumab, infliximab, abatacept, rituximab, and tocilizumab, respectively. Overall, 2,530 hospitalized infections were identified during follow-up, with variation in the incidence rates from 13.1 for abatacept to 18.7 for rituximab per 100 person-years. Compared with abatacept, the hazard ratios were significantly higher for etanercept, infliximab, and rituximab after adjustment (hazard ratios, 1.24, 1.39, and 1.36, respectively).

"In conclusion, we found that among Medicare RA patients with prior exposure to at least one biologic and who were switching to a new agent, that infliximab, rituximab, and etanercept were significantly associated with a greater one-year risk of serious infection compared to abatacept," the authors write. "The choice of biologic therapies among RA patients may be better informed by the modest differences we found in the safety profiles between the agents we studied."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

Doctors Remove Contact Lens Embedded in Eyelid for Years

Doctors Remove Contact Lens Embedded in Eyelid for ...

Lens was encapsulated within the upper eyelid soft tissue since childhood eye trauma

CDC: Brucellosis in Dogs Remains a Public Health Risk

CDC: Brucellosis in Dogs Remains a Public Health ...

Infection is under-recognized, may remain a threat without stronger intervention measures

is free, fast, and customized just for you!




Already a member?

Sign In Now »